Consensus UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
14.15 ^USD	+2.39%		+3.06%	-5.67%

15/04	UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	MT
03/04	UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	MT

Evolution of the average Target Price on UroGen Pharma Ltd.

Price target over the last 5 years

History of analyst recommendation changes

4037399579f09e2b23e457.NfmwlYTTQnSZh2vlqon51yEEqZBOB6jpZ2jJN0HDRIE.W7LToPa0ET7z8wChh-CssxBCyMkGcuXeODeFfwq5Lu9xjMj_6ZwhQdC2Xw~6db0b53435cfe4d3162fd6e95deb95af

Analyst Recommendations on UroGen Pharma Ltd.

Oppenheimer Adjusts UroGen Pharma Price Target to $34 From $35, Maintains Outperform Rating	15/03	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $32, Maintains Outperform Rating	24/01	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $32 From $33, Maintains Outperform Rating	15/11	MT
HC Wainwright Adjusts Price Target on UroGen Pharma to $54 From $23, Maintains Buy Rating	01/23/01	MT
Goldman Sachs Adjusts UroGen Pharma Price Target to $18 From $11, Maintains Neutral Rating	31/23/31	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $33 From $22, Maintains Outperform Rating	28/23/28	MT
Jefferies Downgrades UroGen Pharma to Hold From Buy, Adjusts Price Target to $10 From $35	08/23/08	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $23 From $26, Keeps Buy Rating	12/22/12	MT
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma	14/22/14	CI
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $21, Maintains Outperform Rating	12/22/12	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	01/22/01	MT
Berenberg Bank Initiates Coverage on UroGen Pharma With Buy Rating, $20 Price Target	27/22/27	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $21 From $30, Maintains Outperform Rating	26/22/26	MT
Goldman Sachs Adjusts UroGen Pharma's Price Target to $11 from $10, Maintains Neutral Rating	22/22/22	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $26 From $34, Reiterates Buy Rating	22/22/22	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rating	18/22/18	MT
UROGEN PHARMA : Goldman Sachs Adjusts Price Target for UroGen Pharma to $27 From $26, Maintains Neutral Rating	17/21/17	MT
UROGEN PHARMA : Oppenheimer Adjusts UroGen Pharma's Price Target to $30 From $34, Maintains Outperform Rating	14/21/14	MT
UROGEN PHARMA : HC Wainwright Adjusts Price Target on UroGen Pharma to $50 From $57, Maintains Buy Rating	27/21/27	MT
UROGEN PHARMA : Oppenheimer Adjusts UroGen Pharma PT to $34 From $40, Maintains Outperform Rating	19/21/19	MT
UROGEN PHARMA : Stifel Adjusts UroGen Pharma's Price Target to $32 from $46, Keeps Buy Rating	05/21/05	MT
UROGEN PHARMA : Oppenheimer Adjusts UroGen Pharma PT to $40 From $48, Maintains Outperform Rating	10/20/10	MT